InsiderTrades.com logo

IMNN Insider Trading

Insider Ownership Percentage: 5.96%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Imunon Insider Trading History Chart

This chart shows the insider buying and selling history at Imunon by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Imunon Share Price & Price History

Current Price: $4.00
Price Change: ▲ Price Increase of +0.05 (1.27%)
As of 12/4/2025 05:00 PM ET

This chart shows the closing price history over time for IMNN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Imunon Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/20/2024Donald P BraunDirectorBuy1,666$17.70$29,488.201,706View SEC Filing Icon  
8/15/2024Stacy LindborgCEOBuy1,666$14.70$24,490.2017,611View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Imunon (NASDAQ:IMNN)

4.47% of Imunon stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at IMNN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Imunon Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/12/2025Riverview Capital Advisers LLC34,364$0.18M0.1%+193.3%1.408%Search for SEC Filing on Google Icon
2/13/2025Renaissance Technologies LLC33,561$32K0.0%-47.2%0.231%Search for SEC Filing on Google Icon
2/12/2025Geode Capital Management LLC139,505$0.13M0.0%+10.8%0.962%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Imunon logo
Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
Read More on Imunon

Today's Range

Now: $4.00
Low: $3.90
High: $4.08

50 Day Range

MA: $4.50
Low: $3.64
High: $5.44

52 Week Range

Now: $4.00
Low: $3.56
High: $41.22

Volume

58,567 shs

Average Volume

38,957 shs

Market Capitalization

$12.28 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.94

Who are the company insiders with the largest holdings of Imunon?

Imunon's top insider shareholders include:
  1. Stacy Lindborg (CEO)
  2. Donald P Braun (Director)
Learn More about top insider investors at Imunon.

Who are the major institutional investors of Imunon?

Imunon's top institutional investors include:
  1. Riverview Capital Advisers LLC — 1.41%
Learn More about top institutional investors of Imunon stock.

Which institutional investors are buying Imunon stock?

In the last quarter, IMNN stock was purchased by institutional investors including:
  1. Riverview Capital Advisers LLC
During the last year, these company insiders have bought Imunon stock:
  1. Stacy Lindborg (CEO)
  2. Donald P Braun (Director)
Learn More investors buying Imunon stock.